82.78
+1.51%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anuh Pharma
Its shares trade on NSE under the ticker ANUHPHR.NS. It has been listed since 19 April 1995. In the fiscal year to 31 March 2026, it reported revenue of ₹7.72bn and net income of ₹410.5m. At that date it held total assets of ₹5.57bn and shareholders' equity of ₹3.52bn.
Anuh Pharma Ltd. engages in the manufacture of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing active pharmaceutical ingredients (API). The firm manufactures Macrolides, Anti-TB, Anti-Bacterials, Anti-Malarial, Anti-Hypertension, Expectorant and Corticosteroids products. Its Macrolides products include Erythromycin, Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate and Azithromycin. Its Anti-TB products include Pyrazinamide and Isoniazid. Its Anti-Malarial products include Sulfadoxine and Pyrimethamine. Anti-Bacterials products include Chloramphenicol and Chloramphenicol Palmitate. Anti-Hypertension products include Losartan Potassium, Telmisartan and Atorvastatin Calcium. Its Expectorant product includes Ambroxol Hydrochloride. Its Quinolones product includes Moxifloxacin Hydrochloride.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Apr 1995
- Employees
- 159
- Website
- anuhpharma.com ↗
Leadership
Pay as last reported
- Mr. Arun TodarwalNon-Executive Chairman of the Board₹370,000
- Shri. Bipin ShahNon-Executive Vice Chairman of the Board, since 2021₹310,000
- Mr. Darshan RampariyaChief Financial Officer
- Mr. Manan VadhanCompliance Officer, Company Secretary
- Mr. Ritesh Bipin ShahJoint Managing Director, Executive Director₹4.0m
- Mr. Vivek ShahJoint Managing Director, Executive Director₹4.3m
- Shri. Bharat ShahNon-Executive Non-Independent Director₹210,000
- Mr. Gaurav ShahAdditional Non-Executive Non-Independent Director
- Mr. Ketan ShahNon-Executive Director₹125,000
- Mr. Samir ShahNon-Executive Director₹125,000
- Dr. Mita DixitAdditional Non-Executive Independent Woman Director₹150,000
- Mr. Harmanbhai PatelNon-Executive Independent Director₹250,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Manufactures key pharmaceutical products like Macrolides and Anti-TB in Mumbai
- Produces essential medicines including Erythromycin and Isoniazid for global markets
- Employs 159 skilled workers focused on API manufacturing in Health Care sector
Weaknesses
- Limited to Mumbai headquarters without international expansion plans
- Relies on specific product lines like Anti-Malarial and Anti-Bacterials
- Operates with a small workforce of 159 employees in a competitive industry
Opportunities
- Growing demand for Anti-Hypertension products such as Losartan Potassium
- Expanding markets for Anti-Malarial medicines like Sulfadoxine
- Increasing need for Corticosteroids in global health care systems
Threats
- Competition from larger pharmaceutical firms in India
- Regulatory challenges in API manufacturing processes
- Rising costs for raw materials in the Health Care sector (Pharmaceuticals)
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.